Skip to main content

Industry Partners

PHSA’s Technology Development Office acts as a networking resource to connect industry with the research and technology expertise at all PHSA programs.

The PHSA Technology Development Office (TDO) helps manage interactions between scientists, clinicians and industry partners to promote the development of relationships and to explore opportunities for translating discoveries into innovations.

Industry partners are invited to contact the TDO for any of the following:


The TDO can assist in connecting industry partners with new technologies developed at BC Cancer and other PHSA programs. Please contact us for more information.

Currently, technologies available for licensing include:

‎ABySS software is a novel parallel algorithm to assemble short sequencing data. 


We have identified Connective Tissue-Activating Peptide III (CTAP III) as a novel blood-based biomarker to detect pre-clinical lung cancer up to 29 months before clinical diagnosis. 

We used a novel approach to biomarker discovery that used the same subject as his/her own control to identify elevated proteins in the pulmonary venous effluent draining the tumour vascular bed compared to matched systemic arterial blood. 

Furthermore, CTAP III was found to decrease in patients who are cured by surgery but remains elevated in those who later develop recurrent disease. 

Lung cancer is the most common cause of cancer deaths worldwide, with more than 1.2 million people dying of the disease annually. The overall 5-year survival is only 16%. 

However, if lung cancer is diagnosed and treated in the pre-invasive and early invasive stage (Stage 0/IA), the 5-year survival is 70-90%. 

In patients with larger lung cancer and those with cancer spread to regional lymph nodes within the lung, surgical resection still offers a chance of cure but 50% will develop tumour recurrence despite what appears to be complete surgical removal. 

Adjuvant chemotherapy improves survival in these patients. However, to cure one additional patient over and above surgical resection alone, it is necessary to treat 10 to 20 patients. For patients that do not benefit from chemotherapy, side-effects negatively influence the quality of life and are associated with a 1% risk of fatal toxicity. 

A promising strategy to reduce lung cancer mortality is to detect lung cancer early and offer adjuvant chemotherapy only to those with microscopic residual disease after surgical resection.

Currently, there are no diagnostic tests available to reliably detect lung cancer at the earliest pre-clinical stage or monitor patient outcome after treatment with curative  intent. CTAP III is a novel blood-based biomarker with the potential to detect pre-clinical lung cancer up to two years prior to clinical presentation.


Patient transport between hospitals in different cities is a frequent requirement where very specialized medical procedures, e.g. critical care interventions such extracorporeal life support (ECLS), are restricted to regional centres. 

Patient movement under these circumstances is complex: Not only has the patient to be moved, but also all of the life support equipment such as ECLS circuit, ventilator, IV, etc., without interruption of function. All this equipment has to be placed on top of a stretcher, under tight space limitations, so that everything can fit into an ambulance, helicopter and/or aircraft but still be accessible to care-givers.

The development of ECLS technology has enabled transport of ECLS-dependent patients in who are in need of an intervention such as transplantation which is only available elsewhere. Until today, there was no commercially available transport solution for ECLS-dependent patients: each centre that has transported patients has developed their own system or one-off creation.

Research materials

The TDO can help industry partners enter into a material transfer agreement (MTA) to receive BC Cancer research materials. Please contact us for more information.

We can also connect you to the right person if you're interested in receiving research materials developed at another PHSA program.

Discussing opportunities

Sponsored research and collaborative research agreements are the first step to developing valuable partnerships and intellectual property. If you'd like to discuss a potential collaboration or obtain more information about a researcher at BC Cancer or PHSA, please contact us.

If your discussions include proprietary or confidential information, the TDO can prepare and execute a confidential disclosure agreement (CDA) on behalf of PHSA.

SOURCE: Industry Partners ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © Provincial Health Services Authority. All Rights Reserved.

    Copyright © 2023 Provincial Health Services Authority